{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-030535","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2023-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.328931+00:00","generated_at":"2026-06-13T14:58:14.202719+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rallybio appoints Stephen Uden as CEO effective Aug 1; Martin Mackay becomes Executive Chairman","bullets":["Stephen Uden, current President and COO, named CEO effective Aug 1, 2023; will also join the Board.","Co-founder Martin Mackay transitions from CEO to Executive Chairman, remains full-time employee focusing on strategy and IR.","Phase 1 multiple dose cohort data for RLYB212 and initial data for RLYB116 expected in Q4 2023.","Board size increased to 11 directors; Uden appointed as Class II director with term through 2026 annual meeting.","Uden's base salary stays at $530,000, target bonus 45%; Mackay's compensation unchanged; severance terms similar."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-030535","json":"https://secwatch.observer/filing/0000950170-23-030535.json","markdown":"https://secwatch.observer/filing/0000950170-23-030535.md","text":"https://secwatch.observer/filing/0000950170-23-030535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000095017023030535/0000950170-23-030535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000095017023030535/rlyb-20230628.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:58:14.202719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a7ba155bd","claim":"Stephen Uden was appointed as Chief Executive Officer at Rallybio Corp.","evidence_excerpt":"On June 28, 2023, the Board of Directors (the Board) of Rallybio Corporation (Rallybio) appointed Stephen Uden, M.D., Rallybio’s President, Chief Operating Officer and Co-Founder since January 2018, to Chief Executive Officer, effective August 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000095017023030535/0000950170-23-030535-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"cfb7e799bf","claim":"Martin Mackay was appointed as Executive Chairman at Rallybio Corp.","evidence_excerpt":"Dr. Mackay, who has served as Chief Executive Officer and Chairman of the Board since 2018, has been appointed to Executive Chairman, effective August 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000095017023030535/0000950170-23-030535-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}